Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI

NMR in Biomedicine

Volumn 24, Issue 6, 2011, Pages 734-749

  Nelson, Sarah J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Brain tumors; Diffusion; MRS; Perfusion; Therapeutic response

Indexed keywords

ADJUVANT THERAPY; ANTI-PROLIFERATIVE; BRAIN TUMORS; CLINICAL TRIAL; MRS; NORMAL TISSUE; OVERALL SURVIVAL; PERFUSION; PHASE I; PHASE II; RELIABLE ASSESSMENT; SPATIAL RESOLUTION; SPECTROSCOPIC IMAGING; TARGETED DRUG DELIVERY; THERAPEUTIC RESPONSE; TREATMENT EFFECTS; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR CELLS;

DIAGNOSIS; DISEASE CONTROL; DRUG DELIVERY; GADOLINIUM; HISTOLOGY; IMAGING TECHNIQUES; METABOLISM; PHYSIOLOGY; RATING; SURGERY; TUMORS;

PHYSIOLOGICAL MODELS;

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBON 13; CHOLINE; ENZASTAURIN; GADOLINIUM; TEMOZOLOMIDE;

ANGIOGENESIS; ASTROCYTOMA; BLOOD BRAIN BARRIER; BLOOD VESSEL PERMEABILITY; BRAIN DAMAGE; BRAIN TUMOR; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CARBON NUCLEAR MAGNETIC RESONANCE; CELL HYPOXIA; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); CONTRAST ENHANCEMENT; CYBERKNIFE; CYTOTOXICITY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION WEIGHTED IMAGING; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FRACTIONAL ANISOTROPY; GAMMA KNIFE RADIOSURGERY; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; NEUROANATOMY; NEUROIMAGING; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PERFUSION WEIGHTED IMAGING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR CELL; TUMOR LOCALIZATION; TUMOR VOLUME; VOXEL BASED MORPHOMETRY;

BRAIN NEOPLASMS; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; PATIENT CARE PLANNING; TREATMENT OUTCOME;

EID: 79960834249     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1669     Document Type: Review

References (167)

1. Kleihues P, Burger PC, Scheithauer BW.The new WHO classification of brain tumours.Brain Pathol. 1993;3:255-268.
2. Daumas-Duport C, Tucker ML, Kolles H, Cervera P, Beuvon F, Varlet P, Udo N, Koziak M, Chodkiewicz JP.Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria. J. Neurooncol. 1997;34:61-78.
3. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P.The 2007 WHO classification of tumours of the central nervous system.Acta Neuropathol. 2007;114:97-109.
4. Brat DJ, Scheithauer BW, Fuller GN, Tihan T.Newly codified glial neoplasms of the 2007 WHO classification of tumours of the central nervous system: angiocentric glioma, pilomyxoid astrocytoma and pituicytoma.Brain Pathol. 2007;17:319-324.
5. Folkman J.The role of angiogenesis in tumor growth.Semin. Cancer. Biol. 1992;3:65-71.
6. Wesseling P, Ruiter DJ, Burger P.Angiogenesis in brain tumors: pathobiological and clinical aspects.J. Neurooncol. 1997;32:253-265.
7. Sharma S, Sharma MC, Gupta DK, Sarkar C.Angiogenic patterns and their quantitation in high grade astrocytic tumors.J. Neurooncol. 2006;79:19-30.
8. Schneider SW, Ludwig T, Tatenhorst L, Braune S, Oberleithner H, Senner V, Paulus W.Glioblastoma cells release factors that disrupt blood brain barrier features.Acta Neuropathol. 2004;107:272-276.
9. Ashby LS, Shapiro WR.Low-grade glioma: supratentorial astrocytoma, oligodendroglioma and oligoastrocytoma in adults.Curr. Neurol. Neurosci. Rep. 2004;4:211-217.
10. Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, Afra D, Cornu P, Bolla M, Vecht C, Karim AB.European Organization for Research and Treatment of Cancer Brain Tumor Cooperative Group; European Organization for Research and Treatment of Cancer Radiotherapy Cooperative Group. Prognostic factors for survival in adult patients with cerebral low-grade glioma.J. Clin. Oncol. 2002;20:2076-2084.
11. Yeh SA, Ho JT, Lui CC, Huang YJ, Hsiung CY, Huang EY.Treatment outcomes and prognostic factors in patients with supratentorial low grade gliomas.Br. J. Radiol. 2005;78:230-235.
12. Lang F, Gilbert M.Diffusely infiltrative low grade gliomas in adults.J. Clin. Oncol. 2006;24:1236-1245.
13. Wallner KE, Galicich JH, Krol G, Arbit E, Malkin MG.Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma.Int. J. Radiat. Oncol. Biol. Phys. 1989;16:1405-1409.
14. Chan JL, Lee SW, Fraass BA, Normolle DP, Greenberg HS, Junck LR, Gebarski SS, Sandler HM.Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy.J. Clin. Oncol. 2002;20:1635-1642.
15. Garden AS, Maor MH, Yung WK, Bruner JM, Woo SY, Moser RP, Lee YY.Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas.Radiother. Oncol. 1991;20:99-110.
16. Liang BC, Thornton AF Jr, Sandler HM, Greenberg HS.Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy.J. Neurosurg. 1991;75:559-563.
17. Nakagawa K, Aoki Y, Fujimaki T, Tago M, Terahara A, Karasawa K, Sakata K, Sasaki Y, Matsutani M, Akanuma A.High-dose conformal radiotherapy influenced the pattern of failure but did not improve survival in glioblastoma multiforme.Int. J. Radiat. Oncol. Biol. Phys. 1998;40:1141-1149.
18. Walker MD, Strike TA, Sheline GE.An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.Int. J. Radiat. Oncol. Biol. Phys. 1979;5:1725-1731.
19. Bleehen NM, Stenning SP.A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party.Br. J. Cancer, 1991;64:769-774.
20. Sultanem K, Patrocinio H, Lambert C, Corns R, Leblanc R, Parker W, Shenouda G, Souhami L.The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial.Int. J. Radiat. Oncol. Biol. Phys. 2004;58:247-252.
21. Floyd NS, Woo SY, Teh BS, Prado C, Mai WY, Trask T, Gildenberg PL, Holoye P, Augspurger ME, Carpenter LS, Lu HH, Chiu JK, Grant WH 3rd, Butler EB.Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme.Int. J. Radiat. Oncol. Biol. Phys. 2004;58:721-726.
22. Souhami L, Seiferheld W, Brachman D, Podgorsak EB, Werner-Wasik M, Lustig R, Schultz CJ, Sause W, Okunieff P, Buckner J, Zamorano L, Mehta MP, Curran WJ Jr.Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol.Int. J. Radiat. Oncol. Biol. Phys. 2004;60:853-860.
23. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO.European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.N. Engl. J. Med. 2005;352:987-996.
24. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R.MGMT gene silencing and benefit from temozolomide in glioblastoma.N. Engl. J. Med. 2005;352:997-1003.
25. Brada M, Viviers L, Abson C, Hines F, Britton J, Ashley S, Sardell S, Traish D, Gonsalves A, Wilkins P, Westbury C.Phase II study of primary temozolomide chemotherapy on patients with WHO grade II gliomas.Ann. Oncol. 2003;14:1715-1721.
26. Hoang-Xuan K, Caplelle L, Kujas M, Taillibert S, Duffau H, Lejeune J, Polivka M, Crinière E, Marie Y, Mokhtari K, Carpentier AF, Laigle F, Simon JM, Cornu P, Broët P, Sanson M, Delattre JY.Temozolomide as initial treatment for adults with low grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions.J. Clin. Oncol. 2004;22:3133-3188.
27. Quinn JA, Reardon DA, Freidman AH, Rich JN, Sampson JH, Provenzale JM, McLendon RE, Gururangan S, Bigner DD, Herndon JE 2nd, Avgeropoulos N, Finlay J, Tourt-Uhlig S, Affronti ML, Evans B, Stafford-Fox V, Zaknoen S, Friedman HS.Phase II trial of temozolomide in patients with progressive low grade glioma.J. Clin. Oncol. 2003;21:646-651.
28. Pace A, Vidiri A, Galie E, Carosi M, Telera S, Cianciulli AM, Canalini P, Giannarelli D, Jandolo B, Carapella CM.Temozolomide chemotherapy for progressive low grade glioma: clinical benefits and radiological response.Ann. Oncol. 2003;14:1722-1726.
29. Buckner JC, Gesme D, O'Fallon JR, Hammack JE, Stafford S, Brown PD, Hawkins R, Scheithauer BW, Erickson BJ, Levitt R, Shaw EG, Jenkins R.Phase II trial of procarbazine, lomustine and vincristine as initial therapy for patients with low grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities.J. Clin. Oncol. 2003;21:251-255.
30. Stege EM, Kros JM, de Bruin HG, Enting RH, van Heuvel I, Looijenga LH, van der Rijt CD, Smitt PA, van den Bent MJ.Successful treatment of low grade oligodendroglial tumors with a chemotherapy regimen of procarbazinem, lomustine and vincristine.Cancer, 2005;103:802-809.
31. Sofietti R, Ruda R, Bradac G, Schiffer D.PCV chemotherapy for recurrent oligodendroglioma and oligoastrocytomas.Neurosurgery, 1998;43:1066-1073.
32. Hess KR, Wong ET, Jaeckle KA, Kyritsis AP, Levin VA, Prados MD, Yung WK.Response and progression in recurrent malignant glioma.Neuro-oncology, 1999;1:282-288.
33. Romanelli P, Conti A, Pontoriero A, Ricciardi GK, Tomasello F, De Renzis C, Innocenzi G, Esposito V, Cantore G.Role of stereotactic radiosurgery and fractionated stereotactic radiotherapy for the treatment of recurrent glioblastoma multiforme.Neurosurg. Focus, 2009;27:E8. Review.
34. Yang I, Han S, Parsa AT.Heat-shock protein vaccines as active immunotherapy against human gliomas.Expert Rev. Anticancer Ther. 2009;9:1577-1582.
35. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH.Convection-enhanced delivery of macromolecules in the brain.Proc. Natl. Acad. Sci. USA, 1994;91:2076-2080.
36. Lieberman DM, Laske DW, Morrison PF, Morrison PF, Dedrick RL, Oldfield EH.Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion.J. Neurosurg. 1995;82:1021-1029.
37. Parney IF, Kunwar S, McDermott M, Berger M, Prados M, Cha S, Croteau D, Puri RK, Chang SM.Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma.J. Neurosurg. 2005;102:267-275.
38. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ.Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.Lancet Oncol. 2008;9:453-461.
39. Chamberlain MC, Glantz MJ, Chalmers L, Van Horn A, Sloan AE.Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma.J. Neurooncol. 2007;82:81-83.
40. Taal W, Brandsma D, de Bruin HG, Bromberg JE, Swaak-Kragten AT, Smitt PA, van Es CA, van den Bent MJ.Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide.Cancer, 2008;113:405-410.
41. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group.Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.N. Engl. J. Med. 2005;352:987-996.
42. de Wit MC, de Bruin HG, Eijkenboom W, Sillevis Smitt PA, van den Bent MJ.Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.Neurology, 2004;63:535-537.
43. Chaskis C, Neyns B, Michotte A, De Ridder M, Everaert H.Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations.Surg. Neurol. 2009;72:423-428.
44. Chamberlain MC, Glantz MJ, Chalmers L, Van Horn A, Sloan AE.Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma.J. Neurooncol. 2007;82:81-83.
45. Brandsma D, van den Bent MJ.Pseudoprogression and pseudoresponse in the treatment of gliomas.Curr. Opin. Neurol. 2009;22(6):633-638.
46. Smith JS, Cha S, Mayo MC, McDermott MW, Parsa AT, Chang SM, Dillon WP, Berger MS.Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury.J. Neurosurg. 2005;103:428-438.
47. Wong ET, Brem S.Taming glioblastoma: targeting angiogenesis.J. Clin. Oncol. 2007;25(30):4705-4706.
48. Norden AD, Drappatz J, Muzikansky A, David K, Gerard M, McNamara MB, Phan P, Ross A, Kesari S, Wen PY.An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma.J. Neurooncol. 2009;92:149-155.
49. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY.Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.Neurology, 2008;70:779-787.
50. Narayana A, Kelly P, Golfinos J, Parker E, Johnson G, Knopp E, Zagzag D, Fischer I, Raza S, Medabalmi P, Eagan P, Gruber ML.Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.J. Neurosurg. 2009;110:173-180.
51. Norden AD, Drappatz J, Wen PY.Novel anti-angiogenic therapies for malignant gliomas.Lancet Neurol. 2008;7:1152-1160.
52. Rubenstein J, Kim J, Ozawa T, Zhang M, Westphal M, Deen DF, Shuman MA.Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption.Neoplasia, 2000;2:306-314.
53. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O.Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.Cancer Cell, 2009;15:220-231.
54. Liu P, Cheng H, Roberts TM, Zhao JJ.Targeting the phosphoinositide 3-kinase pathway in cancer.Nat. Rev. Drug Discov. 2009;8:627-644.
55. Endersby R, Baker SJ.PTEN signaling in brain: neuropathology and tumorigenesis.Oncogene, 2008;27:5416-5430.
56. Chakravarti A, Palanichamy K.Overcoming therapeutic resistance in malignant gliomas: current practices and future directions.Cancer Treat. Res. 2008;139:173-189.
57. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA, Scher H.Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.Clin. Cancer Res. 2003;9:3578-3588.
58. Isaacs JS, Xu W, Neckers L.Heat shock protein 90 as a molecular target for cancer therapeutics.Cancer Cell, 2003;3:213-217.
59. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways.Nature, 2008;455:1061-1068.
60. de Groot JF, Gilbert MR.New molecular targets in malignant gliomas.Curr. Opin. Neurol. 2007;20:712-718.
61. Macdonald D, Cascino T, Schold SJ, Cairncross JG.Response criteria for phase II studies of supratentorial malignant glioma.J. Clin. Oncol. 1990;8:1277-1280.
62. Van den Bent M, Volgelbaum M, Wen P, Macdonald DR, Chang SM.Endpoint assessment in gliomas: novel treatments limit the usefulness of the classical Macdonald criteria.J. Clin. Oncol. 2009;27(18):2905-2908.
63. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM.Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.J. Clin. Oncol. 2010;28(11):1963-1972.
64. Wedeen VJ, Hagmann P, Tseng WY, Reese TG, Weisskoff RM.Mapping complex tissue architecture with diffusion spectrum magnetic resonance imaging.Magn. Reson. Med. 2005;54:1377-1386.
65. Basser PJ, Pierpaoli C.Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI.J. Magn. Reson. B, 1996;111:209-219.
66. Sugahara T, Korogi Y, Kochi M, Ikushima I, Shigematu Y, Hirai T, Okuda T, Liang L, Ge Y, Komohara Y, Ushio Y, Takahashi M.Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas.J. Magn. Reson. Imaging, 1999;9:53-60.
67. Bello L, Castellano A, Fava E, Casaceli G, Riva M, Scotti G, Gaini SM, Falini A.Intraoperative use of diffusion tensor imaging fiber tractography and subcortical mapping for resection of gliomas: technical considerations.Neurosurg. Focus, 2010;28:E6.
68. Berman JI, Berger MS, Chung SW, Nagarajan SS, Henry RG.Accuracy of diffusion tensor magnetic resonance imaging tractography assessed using intraoperative subcortical stimulation mapping and magnetic source imaging.J. Neurosurg. 2007;107:488-494.
69. Bian W, Khayal IS, Lupo JM, McGue C, Vandenberg S, Lamborn KR, Chang SM, Cha S, Nelson SJ.Multiparametric characterization of grade 2 glioma subtypes using magnetic resonance spectroscopic, perfusion, and diffusion imaging.Transl. Oncol. 2009;2:271-280.
70. Khayal IS, Nelson SJ.Characterization of low-grade gliomas using RGB color maps derived from ADC histograms.J. Magn. Reson. Imaging, 2009;30:209-213.
71. Khayal IS, McKnight TR, McGue C, Vandenberg S, Lamborn KR, Chang SM, Cha S, Nelson SJ.Apparent diffusion coefficient and fractional anisotropy of newly diagnosed grade II gliomas.NMR Biomed. 2009;22:449-455.
72. Chang SM, Nelson S, Vandenberg S, Cha S, Prados M, Butowski N, McDermott M, Parsa AT, Aghi M, Clarke J, Berger M.Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma.J. Neurooncol. 2009;92:401-415.
73. Padhani AR, Liu G, Mu-Koh D, Chenevert TL, Thoeny HC, Takahara T, Dzik-Jurasz A, Ross BD, Van Cauteren M, Collins D, Hammoud DA, Rustin GJ, Taouli B, Choyke PL.Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations.Neoplasia, 2009;11:102-125.
74. Crawford FW, Khayal IS, McGue C, Saraswathy S, Pirzkall A, Cha S, Lamborn KR, Chang SM, Berger MS, Nelson SJ.Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM.J. Neurooncol. 2009;91(3):337-351.
75. Yamasaki F, Kurisu K, Satoh K, Arita K, Sugiyama K, Ohtaki M, Takaba J, Tominaga A, Hanaya R, Yoshioka H, Hama S, Ito Y, Kajiwara Y, Yahara K, Saito T, Thohar MA.Apparent diffusion coefficient of human brain tumors at MR imaging.Radiology, 2005;235:985-991.
76. Lam WWM, Poon WS, Metreweil C.Diffusion MR imaging in glioma: does it have any role in the pre-operation determination of grading of glioma?Clin. Radiol. 2002;57:219-225.
77. Inoue T, Ogasawara K, Beppu T, Ogawa A, Kabasawa H.Diffusion tensor imaging for preoperative evaluation of tumor grade in gliomas.Clin. Neurol. Neurosurg. 2005;107:174-180.
78. Pirzkall A, McGue C, Saraswathy S, Cha S, Liu R, Vandenberg S, Lamborn KR, Berger MS, Chang SM, Nelson SJ.Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma.Neuro-oncology, 2009;11:842-852.
79. Saraswathy S, Crawford FW, Lamborn KR, Pirzkall A, Chang S, Cha S, Nelson SJ.Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy.J. Neurooncol. 2009;91:69-81.
80. Oztürk A, Oǧuz KK, Akalan N, Geyik PO, Cila A.Evaluation of parenchymal changes at the operation site with early postoperative brain diffusion-weighted magnetic resonance imaging.Diagn. Interv. Radiol. 2006;12:115-120.
81. Chenevert TL, Stegman LD, Taylor JM, Robertson PL, Greenberg HS, Rehemtulla A, Ross BD.Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.J. Natl. Cancer Inst. 2000;92:2029-2036.
82. Mardor Y, Roth Y, Lidar Z, Jonas T, Pfeffer R, Maier SE, Faibel M, Nass D, Hadani M, Orenstein A, Cohen JS, Ram Z.Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging.Cancer Res. 2001;61:4971-4973.
83. Mardor Y, Pfeffer R, Spiegelmann R, Roth Y, Maier SE, Nissim O, Berger R, Glicksman A, Baram J, Orenstein A, Cohen JS, Tichler T.Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging.J. Clin. Oncol. 2003;21:1094-1100.
84. Moffat BA, Chenevert TL, Lawrence TS, Meyer CR, Johnson TD, Dong Q, Tsien C, Mukherji S, Quint DJ, Gebarski SS, Robertson PL, Junck LR, Rehemtulla A, Ross BD.Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response.Proc. Natl. Acad. Sci. USA, 2005;102:5524-5529.
85. Hamstra DA, Chenevert TL, Moffat BA, Johnson TD, Meyer CR, Mukherji SK, Quint DJ, Gebarski SS, Fan X, Tsien CI, Lawrence TS, Junck L, Rehemtulla A, Ross BD.Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma.Proc. Natl. Acad. Sci. USA, 2005;102:16759-16764.
86. Moffat BA, Chenevert TL, Meyer CR, McKeever PE, Hall DE, Hoff BA, Johnson TD, Rehemtulla A, Ross BD.The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome.Neoplasia, 2006;8:259-267.
87. Hamstra DA, Rehemtulla A, Ross BD.Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology.J. Clin. Oncol. 2007;25:4104-4109.
88. Hamstra DA, Galban CJ, Meyer CR, Johnson TD, Sundgren PC, Tsien C, Lawrence TS, Junck L, Ross DJ, Rehemtulla A, Ross BD, Chenevert TL.Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival.J. Clin. Oncol. 2008;26:3387-3394.
89. Minamikawa S, Kono K, Nakayama K, Yokote H, Tashiro T, Nishio A, Hara M, Inoue Y.Glucocorticoid treatment of brain tumor patients: changes of apparent diffusion coefficient values measured by MR diffusion imaging.Neuroradiology, 2004;46:805-811.
90. Khayal IS, Polley MY, Jalbert L, Elkhaled A, Chang SM, Cha S, Butowski NA, Nelson SJ.Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme.Neuro-oncology, 2010;12:908-916.
91. Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, Sai V, Young JR, Tekchandani L, Cloughesy T, Mischel PS, Lai A, Nghiemphu P, Rahmanuddin S, Goldin J.Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.Radiology, 2009;252:182-189.
92. Li Y, Lupo JM, Polley M, Crane JC, Bian W, Cha S, Chang SM, Nelson SJ.Serial analysis of imaging parameters in patients with newly diagnosed glioblastoma multiforme.Neuro-oncology, 2011; DOI:10.1093/neuonc/noq194.
93. Tozer DJ, Jäger HR, Danchaivijitr N, Benton CE, Tofts PS, Rees JH, Waldman AD.Apparent diffusion coefficient histograms may predict low-grade glioma subtype.NMR Biomed. 2007;20:49-57.
94. 1H HR-MAS spectroscopy.Proceedings of the 18th Annual Meeting ISMRM.Stockholm: Sweden, 2010;2203.
95. Rosen BR, Belliveau JW, Chien D.Perfusion imaging by nuclear magnetic resonance.Magn. Reson. Q. 1989;5:263-281.
96. Edelman RR, Mattle HP, Atkinson DJ, Hill T, Finn JP, Mayman C, Ronthal M, Hoogewoud HM, Kleefield J.Cerebral blood flow: assessment with dynamic contrast-enhanced T2*-weighted MR imaging at 1.5 T.Radiology, 1990;176:211-220.
97. Aronen HJ, Gazit IE, Louis DN, Buchbinder BR, Pardo FS, Weisskoff RM, Harsh GR, Cosgrove GR, Halpern EF, Hochberg FH.Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings.Radiology, 1994;191:41-51.
98. Guckel F, Brix G, Rempp K, Deimling M, Rother J, Georgi M.Assessment of cerebral blood volume with dynamic susceptibility contrast enhanced gradient-echo imaging.J. Comput. Assist. Tomogr. 1994;18:344-351.
99. Knopp EA, Cha S, Johnson G, Mazumdar A, Golfinos JG, Zagzag D, Miller DC, Kelly PJ, Kricheff II.Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging.Radiology, 1999;211:791-798.
100. Sugahara T, Korogi Y, Kochi M, Ikushima I, Hirai T, Okuda T, Shigematsu Y, Liang L, Ge Y, Ushio Y, Takahashi M.Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas.Am. J. Roentgenol. 1998;171:1479-1486.
101. Lee MC, Chang SM, Cha S, Nelson SJ.Dynamic susceptibility contrast perfusion imaging of radiation effects in normal appearing brain tissue: changes in the first-pass and recirculation phases.J. Magn. Reson. Imaging, 2005;21:683-693.
102. Lupo JM, Cha S, Sadarangani P, Chang S, Nelson SJ.Dynamic susceptibility-weighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity.Am. J. Neuroradiol. 2005;26:1446-1454.
103. Lupo JM, Cha S, Chang SM, Nelson SJ.Analysis of metabolic indices in regions of abnormal perfusion in patients with high-grade glioma.Am. J. Neuroradiol. 2007;28:1455-1461.
104. Lacerda S, Law M.Magnetic resonance perfusion and permeability imaging in brain tumors.Neuroimaging Clin. N. Am. 2009;19:527-557.
105. Mills SJ, Soh C, O'Connor JP, Rose CJ, Buonaccorsi G, Cheung S, Zhao S, Parker GJ, Jackson A.Enhancing fraction in glioma and its relationship to the tumoral vascular microenvironment: a dynamic contrast-enhanced MR imaging study.Am. J. Neuroradiol. 2010;31:726-731.
106. Barboriak DP, MacFall JR, Viglianti BL, Dewhirst Dvm MW.Comparison of three physiologically-based pharmacokinetic models for the prediction of contrast agent distribution measured by dynamic MR imaging.J. Magn. Reson. Imaging, 2008;27:1388-1398.
107. Evelhoch J, Garwood M, Vigneron D, Knopp M, Sullivan D, Menkens A, Clarke L, Liu G.Expanding the use of magnetic resonance in the assessment of tumor response to therapy: workshop report.Cancer Res. 2005;65:7041-7044.
108. Ashton E, Raunig D, Ng C, Kelcz F, McShane T, Evelhoch J.Scan-rescan variability in perfusion assessment of tumors in MRI using both model and data-derived arterial input functions.J. Magn. Reson. Imaging, 2008;28:791-796.
109. Ferl GZ, Xu L, Friesenhahn M, Bernstein LJ, Barboriak DP, Port RE.An automated method for nonparametric kinetic analysis of clinical DCE-MRI data: application to glioblastoma treated with bevacizumab.Magn. Reson. Med. 2010;63:1366-1375.
110. Harrer JU, Parker GJ, Haroon HA, Buckley DL, Embelton K, Roberts C, Balriaux D, Jackson A.Comparative study of methods for determining vascular permeability and blood volume in human gliomas.J. Magn. Reson. Imaging, 2004;20(5):748-757.
111. Tofts PS, Kermode AG.Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts.Magn. Reson. Med. 1991;17:357-367.
112. Hu LS, Baxter LC, Pinnaduwage DS, Paine TL, Karis JP, Feuerstein BG, Schmainda KM, Dueck AC, Debbins J, Smith KA, Nakaji P, Eschbacher JM, Coons SW, Heiserman JE.Optimized preload leakage-correction methods to improve the diagnostic accuracy of dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in posttreatment gliomas.Am. J. Neuroradiol. 2010;31:40-48.
113. Hu LS, Baxter LC, Smith KA, Feuerstein BG, Karis JP, Eschbacher JM, Coons SW, Nakaji P, Yeh RF, Debbins J, Heiserman JE.Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements.Am. J. Neuroradiol. 2009;30:552-558.
114. Paulson ES, Schmainda KM.Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors.Radiology, 2008;249:601-613.
115. Boxerman JL, Schmainda KM, Weisskoff RM.Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not.Am. J. Neuroradiol. 2006;27:859-867.
116. Law M, Yang S, Wang H, Babb JS, Johnson G, Cha S, Knopp EA, Zagzag D.Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging.Am. J. Neuroradiol. 2003;24:1989-1998.
117. Catalaa I, Henry R, Dillon WP, Graves EE, McKnight TR, Lu Y, Vigneron DB, Nelson SJ.Perfusion, diffusion and spectroscopy values in newly diagnosed cerebral gliomas.NMR Biomed. 2006;19:463-475.
118. Cha S, Tihan T, Crawford F, Fischbein NJ, Chang S, Bollen A, Nelson SJ, Prados M, Berger MS, Dillon WP.Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging.Am. J. Neuroradiol. 2005;26:266-273.
119. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK.AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.Cancer Cell, 2007;11:83-95.
120. Barajas RF Jr, Chang JS, Segal MR, Parsa AT, McDermott MW, Berger MS, Cha S.Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.Radiology, 2009;253:486-496.
121. Essock-Burn E, Lupo JM, Cha S, Polley M, Butowski NA, Chang SM, Nelson SJ.Assessment of perfusion MRI derived parameters in evaluating and predicting response to anti-angiogenic therapy in patients with newly diagnosed GBM.Neuro-oncology, 2011;13(1):119-131.
122. Lupo JM, Banerjee S, Hammond KE, Kelley DA, Xu D, Chang SM, Vigneron DB, Majumdar S, Nelson SJ.GRAPPA-based susceptibility-weighted imaging of normal volunteers and patients with brain tumor at 7 T.Magn. Reson. Imaging, 2009;27:480-488.
123. Lupo JM, Chuang C, Jimenez B, Chang SM, Barani IJ, Hess CP, Nelson SJ.Assessing the effects of radiation therapy on normal brain tissue in patients with glioma using susceptibility-weighted imaging at 7 Tesla.Proceedings of the 18th Annual Meeting ISMRM.Stockholm: Sweden, 2010; Proc. Intl. Soc. Mag. Reson. Med. 18 (2010).
124. Luyten PR, Marien AJ, Heindel W, van Gerwen PH, Herholz K, den Hollander JA, Friedmann G, Heiss WD.Metabolic imaging of patients with intracranial tumors: H-1 MR spectroscopic imaging and PET.Radiology, 1990;176:791-799.
125. 1H NMR spectroscopy in fifty cases of newly diagnosed intracranial tumors.J. Comput. Assist. Tomogr. 1991;15:67-76.
126. 1H NMR spectroscopy in vivo and in vitro.J. Comput. Assist. Tomogr. 1994;18:705-713.
127. Fulham MJ, Bizzi A, Dietz MJ, Shih HH, Raman R, Sobering GS, Frank JA, Dwyer AJ, Alger JR, Di Chiro G.Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance.Radiology, 1992;185:675-686.
128. Negendank WG, Sauter R, Brown TR, Evelhoch JL, Falini A, Gotsis ED, Heerschap A, Kamada K, Lee BC, Mengeot MM, Moser E, Padavic-Shaller KA, Sanders JA, Spraggins TA, Stillman AE, Terwey B, Vogl TJ, Wicklow K, Zimmerman RA.Proton magnetic resonance spectroscopy in patients with glial tumors: a multicenter study.J. Neurosurg. 1996;84:449-458.
129. Preul MC, Caramanos Z, Collins DL, Villemure JG, Leblanc R, Olivier A, Pokrupa R, Arnold DL.Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy.Nat. Med. 1996;2:323-325.
130. Go KG, Kammam RL, Mooyaart EL, Heesters MA, Pruim J, Vaalburg W, Paans AM.Localised proton spectroscopy and spectroscopic imaging in cerebral gliomas, with comparison to positron emission tomography.Neuroradiology, 1995;37(3):198-206.
131. Dowling C, Bollen AW, Noworolski SM, McDermott MW, Barbaro NM, Day MR, Henry RG, Chang SM, Dillon WP, Nelson SJ, Vigneron DB.Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens.Am. J. Neuroradiol. 2001;22:604-612.
132. 1H MRSI.NMR Biomed. 1999;12(3):123-138.
133. Heesters MA, Kamman RL, Mooyaart EL, Go KG.Localized proton spectroscopy of inoperable brain gliomas. Response to radiation therapy.J. Neurooncol. 1993;17:27-35.
134. Li Y, Osorio JA, Ozturk-Isik E, Chen AP, Xu D, Crane JC, Cha S, Chang S, Berger MS, Vigneron DB, Nelson SJ.Considerations in applying 3D PRESS H-1 brain MRSI with an eight-channel phased-array coil at 3 T.Magn. Reson. Imaging, 2006;24:1295-1302.
135. Osorio JA, Ozturk-Isik E, Xu D, Cha S, Chang S, Berger MS, Vigneron DB, Nelson SJ.3D MRSI of brain tumors at 3 Tesla using an 8 channel phased array head coil.J. Magn. Reson. Imaging, 2007;26:23-30.
136. Zierhut ML, Ozturk-Isik E, Chen AP, Park I, Vigneron DB, Nelson SJ.(1)H spectroscopic imaging of human brain at 3 Tesla: comparison of fast three-dimensional magnetic resonance spectroscopic imaging techniques.J. Magn. Reson. Imaging, 2009;30:473-480.
137. Ozturk-Isik E, Crane JC, Cha S, Chang SM, Berger MS, Nelson SJ.Unaliasing lipid contamination for MR spectroscopic imaging of gliomas at 3T using sensitivity encoding (SENSE).Magn. Reson. Med. 2006;55:1164-1169.
138. Ozturk E, Banerjee S, Majumdar S, Nelson SJ.Partially parallel MR spectroscopic imaging of gliomas at3T.Conf. Proc. IEEE Eng. Med. Biol. Soc. 2006;1:493-496.
139. Cheng LL, Ma MJ, Becerra L, Ptak T, Tracey I, Lackner A, González RG.Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy.Proc. Natl. Acad. Sci. USA, 1997;94:6408-6413.
140. Cheng LL, Chang IW, Louis DN, Gonzalez RG.Correlation of high-resolution magic angle spinning proton magnetic resonance spectroscopy with histopathology of intact human brain tumor specimens.Cancer Res. 1998;58:1825-1832.
141. 1H MRS of glial brain tumors: correlation with tissue histology and in vitro MRS.Int. J. Oncol. 1998;12:461-468.
142. McKnight TR, von dem Bussche MH, Vigneron DB, Lu Y, Berger MS, McDermott MW, Dillon WP, Graves EE, Pirzkall A, Nelson S.Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence.J. Neurosurg. 2002;97:794-802.
143. Pirzkall A, McKnight TR, Graves EE, Carol MP, Sneed PK, Wara WW, Nelson SJ, Verhey LJ, Larson DA.MR-spectroscopy guided target delineation for high-grade gliomas.Int. J. Radiat. Oncol. Biol. Phys. 2001;50:915-928.
144. Pirzkall A, Li X, Oh J, Chang S, Berger MS, Larson DA, Verhey LJ, Dillon WP, Nelson SJ.3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI.Int. J. Radiat. Oncol. Biol. Phys. 2004;59:126-137.
145. Graves EE, Nelson SJ, Vigneron DB, Chin C, Verhey L, McDermott M, Larson D, Sneed PK, Chang S, Prados MD, Lamborn K, Dillon WP.A preliminary study of the prognostic value of proton magnetic resonance spectroscopic imaging in gamma knife radiosurgery of recurrent malignant gliomas.Neurosurgery, 2000;46:319-326.
146. Graves EE, Nelson SJ, Vigneron DB, Verhey L, McDermott M, Larson D, Chang S, Prados MD, Dillon WP.Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery.Am. J. Neuroradiol. 2001;22:613-624.
147. Chan AA, Lau A, Pirzkall A, Chang SM, Verhey LJ, Larson D, McDermott MW, Dillon WP, Nelson SJ.Proton magnetic resonance spectroscopy imaging in the evaluation of patients undergoing gamma knife surgery for Grade IV glioma.J. Neurosurg. 2004;101:467-475.
148. 1H MRSI.J. Magn. Reson. Imaging, 2002;16:464-476.
149. Park I, Tamai G, Lee MC, Chuang CF, Chang SM, Berger MS, Nelson SJ, Pirzkall A.Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings.Int. J. Radiat. Oncol. Biol. Phys. 2007;69:381-389.
150. Rock JP, Hearshen D, Scarpace L, Croteau D, Gutierrez J, Fisher JL, Rosenblum ML, Mikkelsen T.Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis.Neurosurgery, 2002;51:912-919.
151. McKnight TR, Noworolski SM, Vigneron DB, Nelson SJ.An automated technique for the quantitative assessment of 3D-MRSI data from patients with glioma.J. Magn. Reson. Imaging, 2001;13:167-177.
152. Lee MC, Pirzkall A, McKnight TR, Nelson SJ.1H-MRSI of radiation effects in normal-appearing white matter: dose-dependence and impact on automated spectral classification.J. Magn. Reson. Imaging, 2004;19:379-388.
153. Matulewicz L, Sokol M, Michnik A, Wydmanski J.Long-term normal-appearing brain tissue monitoring after irradiation using proton magnetic resonance spectroscopy in vivo: statistical analysis of a large group of patients.Int. J. Radiat. Oncol. Biol. Phys. 2006;66:825-832.
154. Esteve F, Rubin C, Grand S, Kolodie H, Le Bas JF.Transient metabolic changes observed with proton MR spectroscopy in normal human brain after radiation therapy.Int. J. Radiat. Oncol. Biol. Phys. 1998;40:279-286.
155. Park I, Chen AP, Zierhut ML, Ozturk-Isik E, Vigneron DB, Nelson SJ.Implementation of 3 T lactate-edited 3D (1)H MR spectroscopic imaging with flyback echo-planar readout for gliomas patients.Ann. Biomed. Eng. 2011;39(1):193-204.
156. Wright AJ, Fellows G, Byrnes TJ, Opstad KS, McIntyre DJ, Griffiths JR, Bell BA, Clark CA, Barrick TR, Howe FA.Pattern recognition of MRSI data shows regions of glioma growth that agree with DTI markers of brain tumor infiltration.Magn. Reson. Med. 2009;62:1646-1651.
157. Opstad KS, Wright AJ, Bell BA, Griffiths JR, Howe FA.Correlations between in vivo (1)H MRS and ex vivo (1)H HRMAS metabolite measurements in adult human gliomas.J. Magn. Reson. Imaging, 2010;31:289-297.
158. Srinivasan R, Phillips JJ, Vandenberg SR, Polley MY, Bourne G, Au A, Pirzkall A, Cha S, Chang SM, Nelson SJ.Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM.Neuro Oncol, 2010;12(11):1152-1161.
159. Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH, Servin R, Thaning M, Golman K.Increase in signal-to-noise ratio of > 10, 000 times in liquid-state NMR.Proc. Natl. Acad. Sci. USA, 2003;100(10):158.
160. Golman K, Zandt R, Thaning M.Real-time metabolic imaging.Proc. Natl. Acad. Sci. USA, 2006;103(30):11270-11275.
161. 13C magnetic resonance imaging for in vivo tumor diagnosis.Cancer Res. 2006;66:10855-10860.
162. 13C magnetic resonance metabolic imaging for cancer applications.Appl. Magn. Reson. 2008;34:533-544.
163. 13C-1-pyruvate.Magn. Reson. Med. 2007;58(1):65-69.
164. 13C spectroscopic imaging of the TRAMP mouse at 3T - initial experience.Magn. Reson. Med. 2007;58:1099-1106.
165. 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading.Cancer Res. 2008;68:8607-8615.
166. 13C magnetic resonance metabolic imaging: application to brain tumors.Neuro-oncology, 2010;12:133-144.
167. 13C MR metabolic imaging.Proceedings of the 18th Annual Meeting ISMRM.Stockholm: Sweden, 2010;3732.